Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 10;148(15):1138-1153.
doi: 10.1161/CIRCULATIONAHA.122.063444. Epub 2023 Sep 25.

Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis

Affiliations

Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis

Nicholas Jex et al. Circulation. .

Abstract

Background: Type 2 diabetes (T2D) is associated with an increased risk of left ventricular dysfunction after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS). Persistent impairments in myocardial energetics and myocardial blood flow (MBF) may underpin this observation. Using phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance, this study tested the hypothesis that patients with severe AS and T2D (AS-T2D) would have impaired myocardial energetics as reflected by the phosphocreatine to ATP ratio (PCr/ATP) and vasodilator stress MBF compared with patients with AS without T2D (AS-noT2D), and that these differences would persist after AVR.

Methods: Ninety-five patients with severe AS without coronary artery disease awaiting AVR (30 AS-T2D and 65 AS-noT2D) were recruited (mean, 71 years of age [95% CI, 69, 73]; 34 [37%] women). Thirty demographically matched healthy volunteers (HVs) and 30 patients with T2D without AS (T2D controls) were controls. One month before and 6 months after AVR, cardiac PCr/ATP, adenosine stress MBF, global longitudinal strain, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk distance were assessed in patients with AS. T2D controls underwent identical assessments at baseline and 6-month follow-up. HVs were assessed once and did not undergo 6-minute walk testing.

Results: Compared with HVs, patients with AS (AS-T2D and AS-noT2D combined) showed impairment in PCr/ATP (mean [95% CI]; HVs, 2.15 [1.89, 2.34]; AS, 1.66 [1.56, 1.75]; P<0.0001) and vasodilator stress MBF (HVs, 2.11 mL min g [1.89, 2.34]; AS, 1.54 mL min g [1.41, 1.66]; P<0.0001) before AVR. Before AVR, within the AS group, patients with AS-T2D had worse PCr/ATP (AS-noT2D, 1.74 [1.62, 1.86]; AS-T2D, 1.44 [1.32, 1.56]; P=0.002) and vasodilator stress MBF (AS-noT2D, 1.67 mL min g [1.5, 1.84]; AS-T2D, 1.25 mL min g [1.22, 1.38]; P=0.001) compared with patients with AS-noT2D. Before AVR, patients with AS-T2D also had worse PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.66 [1.56, 1.75]; P=0.04) and vasodilator stress MBF (AS-T2D, 1.25 mL min g [1.10, 1.41]; T2D controls, 1.54 mL min g [1.41, 1.66]; P=0.001) compared with T2D controls at baseline. After AVR, PCr/ATP normalized in patients with AS-noT2D, whereas patients with AS-T2D showed no improvements (AS-noT2D, 2.11 [1.79, 2.43]; AS-T2D, 1.30 [1.07, 1.53]; P=0.0006). Vasodilator stress MBF improved in both AS groups after AVR, but this remained lower in patients with AS-T2D (AS-noT2D, 1.80 mL min g [1.59, 2.0]; AS-T2D, 1.48 mL min g [1.29, 1.66]; P=0.03). There were no longer differences in PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.51 [1.34, 1.53]; P=0.12) or vasodilator stress MBF (AS-T2D, 1.48 mL min g [1.29, 1.66]; T2D controls, 1.60 mL min g [1.34, 1.86]; P=0.82) between patients with AS-T2D after AVR and T2D controls at follow-up. Whereas global longitudinal strain, 6-minute walk distance, and NT-proBNP all improved after AVR in patients with AS-noT2D, no improvement in these assessments was observed in patients with AS-T2D.

Conclusions: Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.

Keywords: aortic valve stenosis; diabetes mellitus, type 2; magnetic resonance imaging; myocardial blood flow.

PubMed Disclaimer

Conflict of interest statement

Disclosures None.

Figures

Figure 1.
Figure 1.
Consort flow diagram demonstrating the recruitment pathway for study patients with AS. AR indicates atrial regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; CMR, cardiovascular magnetic resonance imaging; EF, ejection fraction; eGFR, estimated glomerular filtration rate; FB, foreign body; HF, heart failure; LVSD, left ventricular systolic dysfunction; NHS, National Health Service; T2D, type 2 diabetes.
Figure 2.
Figure 2.
Multiparametric scan protocol. Cardiac 31P magnetic resonance spectroscopy (MRS) was followed by cardiovascular magnetic resonance imaging, which included cine imaging, native precontrast, and native postcontrast T1 mapping; adenosine stress perfusion imaging; and late gadolinium enhancement (LGE) imaging. SA indicates short axis.
Figure 3.
Figure 3.
Differences in peak diastolic strain rate, global longitudinal strain, myocardial PCr/ATP ratio, and stress MBF between patients with AS both with and without T2D before and 6 months after AVR. Differences in peak diastolic strain rate (s−1; A), global longitudinal strain (−%; B), myocardial phosphocreatine to ATP ratio (PCr/ATP; C), and stress myocardial blood flow (MBF; D) between patients with aortic stenosis (AS) and type 2 diabetes (T2D) vs patients with AS without T2D before and 6 months after aortic valve replacement (AVR).

References

    1. Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, Dobson LE, Pica S, Loudon M, Malley T, et al. Myocardial scar and mortality in severe aortic stenosis. Circulation. 2018;138:1935–1947. doi: 10.1161/CIRCULATIONAHA.117.032839 - PMC - PubMed
    1. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, Yoon S-H, Trento A, Svensson LG, Herrmann HC, et al. ; PARTNER 2 Investigators. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382:799–809. doi: 10.1056/NEJMoa1910555 - PubMed
    1. López-de-Andrés A, Perez-Farinos NA-O, de Miguel-Díez J, Hernández-Barrera V, Méndez-Bailón M, de Miguel-Yanes JM, Jiménez-García R. Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical aortic valve replacement in Spain (2001-2015). Cardiovasc Diabetol. 2018;17:135. doi: 10.1186/s12933-018-0780-2 - PMC - PubMed
    1. Halkos ME, Kilgo P, Lattouf OM, Puskas JD, Cooper WA, Guyton RA, Thourani VH. The effect of diabetes mellitus on in-hospital and long-term outcomes after heart valve operations. Ann Thorac Surg. 2010;90:124–130. doi: 10.1016/j.athoracsur.2010.03.111 - PubMed
    1. Auensen A, Hussain AI, Bendz B, Aaberge L, Falk RS, Walle-Hansen MM, Bye J, Andreassen J, Beitnes JO, Rein KA, et al. Morbidity outcomes after surgical aortic valve replacement. Open Heart. 2017;4:e000588. doi: 10.1136/openhrt-2017-000588 - PMC - PubMed

Publication types